Thursday, 5 November 2026European Markets

EASE2PAY NV Stock Was Up By 20% Before The Weekend

Loading stream...

(VIANEWS) - The Market ended the session with EASE2PAY NV (EAS2P.AS) rising 20% to €0.66 on Friday while AEX-Index slid 0.22% to €730.09.

EASE2PAY NV's last close was €0.55, 75.56% under its 52-week high of €2.25.

About EASE2PAY NV

Ease2pay N.V. provides online payment services and platform in the Netherlands. It offers payment transaction platform, which offers users services to order and pay in one action and parking solutions. The company was formerly known as DOCDATA N.V. and changed its name to Ease2pay N.V. in February 2018. Ease2pay N.V. is headquartered in Waalwijk, the Netherlands. Ease2pay N.V. is a subsidiary of The Internet of Cars V.O.F.

Earnings Per Share

As for profitability, EASE2PAY NV has a trailing twelve months EPS of €-0.1.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -9.6%.

Revenue Growth

Year-on-year quarterly revenue growth grew by 1331%, now sitting on 1.86M for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, EASE2PAY NV's stock is considered to be overbought (>=80).

Yearly Top and Bottom Value

EASE2PAY NV's stock is valued at €0.66 at 22:30 EST, way under its 52-week high of €2.25 and way higher than its 52-week low of €0.56.

More news about EASE2PAY NV (EAS2P.AS).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Oncology Data Season and Biotech Capital Allocation: ESMO Readouts, Ivonescimab PDUFA, and Diverging Corporate Moves
Late-2026 biotech is driven by a dense catalyst calendar. ESMO 2026 delivers data from ivonescimab, Enhertu, R-DXd and bemarituzumab, and the FDA has set a 14 Nov PDUFA date for the ivonescimab BLA. Capital allocation is diverging. Krystal Biotech authorized a $400M buyback while lowering FY2026 spend guidance and pushing milestones into 2027. Spago is moving to delist from Nasdaq First North. The facts are clinical and corporate events, not AI or fintech, so the finance angle is limited to capital markets (buybacks, guidance, delistings, regulatory timelines).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,549 source documents archived
Query this data → isubstrate.com